TIFA

Summary

TIFA (TRAF interacting protein with forkhead associated domain, HGNC:19075) is a protein-coding gene on chromosome 4q25, encoding TRAF-interacting protein with FHA domain-containing protein A (Q96CG3). Adapter molecule that plays a key role in the activation of pro-inflammatory NF-kappa-B signaling following detection of bacterial pathogen-associated molecular pattern metabolites (PAMPs).

This gene encodes an adapter protein involved in adaptive and innate immunity. This protein includes a forkhead-associated (FHA) domain that specifically binds to phosphorylated serine and threonine residues. In response to bacterial infection, the encoded host cell protein undergoes an intermolecular interaction between the FHA domain and a phosphorylated threonine that leads to protein oligomerization and stimulation of the NF-kappa B and other downstream signaling pathways. This protein exhibits reduced expression in hepatocellular carcinoma and may suppress hepatocellular carcinoma progression. This protein may also play a role in the DNA damage response.

Source: NCBI Gene 92610 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 21 total
• MANE Select transcript: NM_052864

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19075
Approved symbol	TIFA
Name	TRAF interacting protein with forkhead associated domain
Location	4q25
Locus type	gene with protein product
Status	Approved
Aliases	MGC20791, T2BP, T6BP, TIFAA
Ensembl gene	ENSG00000145365
Ensembl biotype	protein_coding
OMIM	609028
Entrez	92610

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000361717, ENST00000500655, ENST00000610220, ENST00000897930, ENST00000897931, ENST00000949133

RefSeq mRNA: 1 — MANE Select: NM_052864 NM_052864

CCDS: CCDS34051

Canonical transcript exons

ENST00000361717 — 2 exons

Exon	Start	End
ENSE00000970184	112285640	112285904
ENSE00003993116	112274537	112278434

Expression profiles

Bgee: expression breadth ubiquitous, 233 present calls, max score 98.92.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.0133 / max 187.1907, expressed in 1723 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
53650	5.1331	1502
53649	4.9754	1292
53648	1.7530	931
53651	0.1518	88

Top tissues by expression

252 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	98.92	gold quality
oocyte	CL:0000023	98.45	gold quality
cartilage tissue	UBERON:0002418	94.88	gold quality
parotid gland	UBERON:0001831	93.58	gold quality
esophagus squamous epithelium	UBERON:0006920	93.07	gold quality
buccal mucosa cell	CL:0002336	92.44	gold quality
oral cavity	UBERON:0000167	92.43	gold quality
calcaneal tendon	UBERON:0003701	90.94	gold quality
oviduct epithelium	UBERON:0004804	90.74	gold quality
ileal mucosa	UBERON:0000331	90.57	gold quality
bone marrow	UBERON:0002371	90.25	gold quality
tonsil	UBERON:0002372	90.08	gold quality
bone marrow cell	CL:0002092	90.02	gold quality
body of pancreas	UBERON:0001150	89.78	gold quality
gingiva	UBERON:0001828	89.73	gold quality
gingival epithelium	UBERON:0001949	89.69	gold quality
epithelium of nasopharynx	UBERON:0001951	88.10	gold quality
lymph node	UBERON:0000029	87.95	gold quality
vermiform appendix	UBERON:0001154	87.86	gold quality
upper leg skin	UBERON:0004262	87.80	gold quality
palpebral conjunctiva	UBERON:0001812	87.62	gold quality
pancreas	UBERON:0001264	86.83	gold quality
pigmented layer of retina	UBERON:0001782	85.38	gold quality
germinal epithelium of ovary	UBERON:0001304	85.25	gold quality
tendon	UBERON:0000043	85.20	gold quality
blood	UBERON:0000178	84.88	gold quality
tibia	UBERON:0000979	84.79	gold quality
ganglionic eminence	UBERON:0004023	84.34	gold quality
lower esophagus mucosa	UBERON:0035834	84.26	gold quality
saliva-secreting gland	UBERON:0001044	83.92	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-CURD-112	yes	37.96
E-ANND-3	yes	17.10

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

69 targeting TIFA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-5002-5P	99.76	70.84	1763
HSA-MIR-187-5P	99.74	70.26	1404
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-5004-3P	99.54	68.27	1371
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-513C-5P	99.50	68.42	1730

Literature-anchored findings (GeneRIF, showing 18)

• TIFA induces the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism (PMID:15492226)
• identify a novel threonine phosphorylation site on TIFA and show that this phosphorylated threonine binds with the FHA domain of TIFA, leading to TIFA oligomerization and TIFA-mediated NF-kappaB activation (PMID:22566686)
• an innate immune signaling axis, mediated by phosphorylation-dependent oligomerization of the TRAF-interacting protein with forkhead-associated domain (TIFA) that is triggered by heptose-1,7-bisphosphate. (PMID:26068852)
• This study reports the crystal structures of TIFA (residues 1-150, with the unstructured C-terminal tail truncated) and its complex with the N-terminal phosphothreonine9 peptide (residues 1-15). (PMID:26389808)
• TIFA is a crucial mediator in the endothelial innate immune response by potentiating and amplifying NLRP3 inflammasome via augmenting signals 1 and 2 (PMID:27965388)
• we report that Aurora A is essential for phosphorylation of the TRAF-interacting protein TIFA (PMID:28069801)
• These results define TIFA as a rheostat for intracellular bacterial replication, escalating the immune response to invasive Gram-negative bacteria that exploit the host cytosol for growth. (PMID:28514661)
• study revealed that host TIFA and H. pylori-derived heptose-1,7-bisphosphate are critical effectors of innate immune signaling that account for much of the inflammatory response to H. pylori in gastric epithelial cells (PMID:28811347)
• TIFA expression limited proliferation of multiple myeloma cancer cells. In conclusion these results indicate that TIFA functions as a key transducer in DNA damage-induced NF-kappaB activation (PMID:29581234)
• TIFA may serve as a biomarker in the prediction of lung adenocarcinoma. Furthermore, TIFA may modulate lung cancer cell survival and proliferation through regulating the synthesis of apoptosis-associated proteins. (PMID:29975933)
• The results provide direct evidence and a structural basis for the TIFA-TRAF6 interaction, and show how this important biological function can be modulated. (PMID:30378729)
• REVIEW: various mechanisms and pathways involved in H. pylori induction of NF-kappaB-dependent responses in gastric epithelial cells, including a ‘state-of-the-art’ review on the respective roles of NOD1 and ALPK1/TIFA pathways in these responses (PMID:31123889)
• TIFA and TIFAB: FHA-domain proteins involved in inflammation, hematopoiesis, and disease. (PMID:32910997)
• The ALPK1/TIFA/NF-kappaB axis links a bacterial carcinogen to R-loop-induced replication stress. (PMID:33037203)
• TIFA protein expression is associated with pulmonary arterial hypertension. (PMID:34238983)
• TIFA has dual functions in Helicobacter pylori-induced classical and alternative NF-kappaB pathways. (PMID:34328245)
• TIFA promotes colorectal cancer cell proliferation in an RSK- and PRAS40-dependent manner. (PMID:35635239)
• The potential biomarker TIFA regulates pyroptosis in sepsis-induced acute kidney injury. (PMID:36586274)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	tifa	ENSDARG00000091111
mus_musculus	Tifa	ENSMUSG00000046688
rattus_norvegicus	Tifa	ENSRNOG00000010941

Paralogs (1): TIFAB (ENSG00000255833)

Protein

Protein identifiers

TRAF-interacting protein with FHA domain-containing protein A — Q96CG3 (reviewed: Q96CG3)

Alternative names: Putative MAPK-activating protein PM14, Putative NF-kappa-B-activating protein 20, TRAF2-binding protein

All UniProt accessions (1): Q96CG3

UniProt curated annotations — full annotation on UniProt →

Function. Adapter molecule that plays a key role in the activation of pro-inflammatory NF-kappa-B signaling following detection of bacterial pathogen-associated molecular pattern metabolites (PAMPs). Promotes activation of an innate immune response by inducing the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism. TIFA-dependent innate immune response is triggered by ADP-D-glycero-beta-D-manno-heptose (ADP-Heptose), a potent PAMP present in all Gram-negative and some Gram-positive bacteria: ADP-Heptose is recognized by ALPK1, which phosphorylates TIFA at Thr-9, leading to TIFA homooligomerization and subsequent activation of pro-inflammatory NF-kappa-B signaling.

Subunit / interactions. Homooligomer; homooligomerizes following phosphorylation at Thr-9. Interacts with IRAK1, TRAF2 and TRAF6. Interacts with TIFAB; binding to TIFAB inhibits TRAF6 activation, possibly by inducing a conformational change in TIFA. Interacts with ZCCHC11; binding to ZCCHC11 suppresses the TRAF6-dependent activation of NF-kappa-B.

Subcellular location. Cytoplasm.

Post-translational modifications. Phosphorylated at Thr-9 following detection of ADP-D-glycero-beta-D-manno-heptose (ADP-Heptose) by ALPK1. Phosphorylation at Thr-9 by ALPK1 leads to the formation of an intermolecular binding between the FHA domain and phosphorylated Thr-9, promoting TIFA oligomerization and TIFA-mediated NF-kappa-B activation.

Domain organisation. The FHA domain recognizes and binds phosphorylated Thr-9, promoting homooligomerization and subsequent activation of NF-kappa-B.

Similarity. Belongs to the TIFA family.

RefSeq proteins (1): NP_443096* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000253	FHA_dom	Domain
IPR008984	SMAD_FHA_dom_sf	Homologous_superfamily
IPR033621	TIFA	Family

Pfam: PF00498

UniProt features (31 total): strand 14, mutagenesis site 6, turn 4, chain 1, domain 1, helix 1, region of interest 1, compositionally biased region 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
6A33	X-RAY DIFFRACTION	2.1
5ZUJ	X-RAY DIFFRACTION	2.6
4ZGI	X-RAY DIFFRACTION	2.7
4YM4	X-RAY DIFFRACTION	3.12

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96CG3-F1	87.12	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 9

Mutagenesis-validated functional residues (6):

Position	Phenotype
88–89	in rkn: loss of homooligomerization and activation of nf-kappa-b and jnk pathways; when associated with a-51.
178	loss of binding to traf6 and activation of nf-kappa-b and jnk pathways.
9	abolishes phosphorylation by alpk1 and subsequent tifa-mediated nf-kappa-b activation.
50	loss of homooligomerization and activation of nf-kappa-b and jnk pathways; when associated with a-66.
51	in rkn: loss of homooligomerization and activation of nf-kappa-b and jnk pathways; when associated with 88-a-a-89.
66	loss of homooligomerization and activation of nf-kappa-b and jnk pathways; when associated with e-50.

Function

Pathways and Gene Ontology

Reactome pathways

24 pathways

ID	Pathway
R-HSA-445989	TAK1-dependent IKK and NF-kappa-B activation
R-HSA-9645460	Alpha-protein kinase 1 signaling pathway
R-HSA-1280215	Cytokine Signaling in Immune system
R-HSA-166016	Toll Like Receptor 4 (TLR4) Cascade
R-HSA-166058	MyD88:MAL(TIRAP) cascade initiated on plasma membrane
R-HSA-166166	MyD88-independent TLR4 cascade
R-HSA-168138	Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168142	Toll Like Receptor 10 (TLR10) Cascade
R-HSA-168164	Toll Like Receptor 3 (TLR3) Cascade
R-HSA-168176	Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168179	Toll Like Receptor TLR1:TLR2 Cascade
R-HSA-168181	Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168188	Toll Like Receptor TLR6:TLR2 Cascade
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-168898	Toll-like Receptor Cascades
R-HSA-181438	Toll Like Receptor 2 (TLR2) Cascade
R-HSA-446652	Interleukin-1 family signaling
R-HSA-449147	Signaling by Interleukins
R-HSA-9020702	Interleukin-1 signaling
R-HSA-937061	TRIF (TICAM1)-mediated TLR4 signaling
R-HSA-975138	TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-975155	MyD88 dependent cascade initiated on endosome
R-HSA-975871	MyD88 cascade initiated on plasma membrane

MSigDB gene sets: 210 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, chr4q25, REACTOME_INNATE_IMMUNE_SYSTEM, ZHAN_MULTIPLE_MYELOMA_PR_DN, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, FISCHER_G1_S_CELL_CYCLE, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOBP_POSITIVE_REGULATION_OF_RESPONSE_TO_EXTERNAL_STIMULUS, GOBP_REGULATION_OF_IMMUNE_RESPONSE

GO Biological Process (6): cytoplasmic pattern recognition receptor signaling pathway (GO:0002753), tumor necrosis factor-mediated signaling pathway (GO:0033209), positive regulation of canonical NF-kappaB signal transduction (GO:0043123), innate immune response (GO:0045087), protein homooligomerization (GO:0051260), immune system process (GO:0002376)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-16 pathways:

Category	Pathways
Toll-like Receptor Cascades	7
Innate Immune System	2
Immune System	2
Toll Like Receptor 4 (TLR4) Cascade	2
Toll Like Receptor 2 (TLR2) Cascade	2
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	1
Toll Like Receptor 3 (TLR3) Cascade	1
Interleukin-1 signaling	1
TRIF (TICAM1)-mediated TLR4 signaling	1
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	1
MyD88 cascade initiated on plasma membrane	1
Toll Like Receptor TLR1:TLR2 Cascade	1
Toll Like Receptor TLR6:TLR2 Cascade	1
Signaling by Interleukins	1
Cytokine Signaling in Immune system	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
positive regulation of cytokine production	1
pattern recognition receptor signaling pathway	1
intracellular receptor signaling pathway	1
cytokine-mediated signaling pathway	1
cellular response to tumor necrosis factor	1
canonical NF-kappaB signal transduction	1
regulation of canonical NF-kappaB signal transduction	1
positive regulation of intracellular signal transduction	1
immune response	1
defense response to symbiont	1
protein complex oligomerization	1
biological_process	1
binding	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

377 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TIFA	TRAF6	Q9Y4K3	822
TIFA	ALPK1	Q96QP1	770
TIFA	TANK	Q92844	720
TIFA	IRAK1	P51617	675
TIFA	TRAF2	Q12933	535
TIFA	THEMIS	Q8N1K5	462
TIFA	TRAF5	O00463	452
TIFA	TRAF3	Q13114	438
TIFA	SPHK1	Q9NYA1	423
TIFA	NFKB1	P19838	418
TIFA	TRAF1	Q13077	401
TIFA	BIRC2	Q13490	394
TIFA	NOD1	Q9Y239	393
TIFA	TNFRSF8	P28908	387
TIFA	TAX1BP1	Q86VP1	387

IntAct

107 interactions, top by confidence:

A	B	Type	Score
TIFA	TRAF2	psi-mi:“MI:0915”(physical association)	0.840
TRAF2	TIFA	psi-mi:“MI:0915”(physical association)	0.840
SDCBP	TIFA	psi-mi:“MI:0915”(physical association)	0.790
TIFA	SDCBP	psi-mi:“MI:0915”(physical association)	0.790
AP1M1	TIFA	psi-mi:“MI:0915”(physical association)	0.780
TIFA	AP1M1	psi-mi:“MI:0915”(physical association)	0.780
TRAF6		psi-mi:“MI:0914”(association)	0.770
TIFA	SDCBP2	psi-mi:“MI:0915”(physical association)	0.760
SDCBP2	TIFA	psi-mi:“MI:0915”(physical association)	0.760
RPL9	TIFA	psi-mi:“MI:0915”(physical association)	0.720
TIFA	NXF1	psi-mi:“MI:0915”(physical association)	0.720
TIFA	RPL9	psi-mi:“MI:0915”(physical association)	0.720

BioGRID (75): TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid), TIFA (Two-hybrid)

ESM2 similar proteins: A0JM23, A2VDM0, A5WW08, A6NFN9, B5DE70, E9Q173, F6U5F9, H0UZ81, O13034, P0C6R2, P25022, P34089, P50851, P97573, Q0VCL9, Q0VGW0, Q14B46, Q2I0E5, Q2MHQ9, Q32L18, Q32M84, Q3TTL0, Q4QR86, Q5F479, Q5FWP4, Q5JPI3, Q5XGX5, Q5XIB9, Q5ZLG9, Q60760, Q66H33, Q6AXU1, Q6AZT6, Q6AZT7, Q6P256, Q6PJI9, Q793I8, Q7Z494, Q8C0M0, Q8C0W1

Diamond homologs: A2VDM0, B5DE70, Q2MHQ9, Q5XIB9, Q793I8, Q8JZM6, Q96CG3, Q5BK67, Q6ZNK6

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
AKT1	“up-regulates activity”	TIFA	phosphorylation
AURKA	“up-regulates activity”	TIFA	phosphorylation
ALPK1	“up-regulates activity”	TIFA	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

21 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	18
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

1230 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:112278268:C:T	G50D	0.994
4:112278208:A:G	F70S	0.993
4:112278130:A:G	L96P	0.992
4:112278144:A:C	S91R	0.992
4:112278144:A:T	S91R	0.992
4:112278146:T:G	S91R	0.992
4:112278265:C:G	R51P	0.991
4:112278202:A:G	L72P	0.989
4:112278268:C:A	G50V	0.988
4:112278150:A:C	N89K	0.987
4:112278150:A:T	N89K	0.987
4:112278145:C:A	S91I	0.986
4:112278157:A:T	I87K	0.986
4:112278067:A:T	V117D	0.985
4:112278153:T:A	K88N	0.984
4:112278153:T:G	K88N	0.984
4:112278060:G:C	F119L	0.983
4:112278060:G:T	F119L	0.983
4:112278062:A:G	F119L	0.983
4:112278238:A:G	F60S	0.983
4:112278269:C:G	G50R	0.983
4:112278053:A:C	Y122D	0.982
4:112278100:A:G	L106P	0.982
4:112278157:A:C	I87R	0.982
4:112278370:A:G	L16P	0.981
4:112278162:A:C	F85L	0.980
4:112278162:A:T	F85L	0.980
4:112278163:A:G	F85S	0.980
4:112278164:A:G	F85L	0.980
4:112278085:A:G	L111P	0.979

dbSNP variants (sampled 300 via entrez): RS1000037648 (4:112274872 TG>T), RS10000620 (4:112282048 A>C,G,T), RS10000700 (4:112282115 A>C,G), RS1000091899 (4:112286880 G>A,C), RS10003654 (4:112282997 A>G), RS10008828 (4:112283940 T>C), RS1000931130 (4:112274540 T>C), RS1001394391 (4:112281997 A>C,G), RS1001715516 (4:112276480 A>G), RS1001934691 (4:112276108 T>C), RS1001994062 (4:112283413 C>T), RS1002281164 (4:112283237 T>C), RS10026212 (4:112282958 C>G,T), RS10026284 (4:112282900 G>A), RS1002696359 (4:112283907 T>C)

Disease associations

OMIM: gene MIM:609028 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, affects cotreatment, increases expression	7
trichostatin A	affects cotreatment, increases expression	3
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Cyclosporine	decreases expression, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	increases phosphorylation	1
dicrotophos	decreases expression	1
sodium arsenite	decreases expression	1
potassium chromate(VI)	decreases expression	1
vanadyl sulfate	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
clothianidin	increases expression	1
3,4,5,4’-tetramethoxystilbene	affects expression	1
abrine	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
gardiquimod	increases expression, decreases reaction	1
MT19c compound	increases expression	1
Sunitinib	decreases expression	1
Zoledronic Acid	increases expression	1
Vorinostat	increases expression	1
Arsenic	affects methylation	1
Cisplatin	increases expression	1
Formaldehyde	decreases expression	1
Quercetin	decreases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A8BV	HEK-Blue KO-TIFA	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.